U.S.  Implements New Export Controls to Address National Security Risks Related to Biotechnology
| | | | | | | | | | | | |

U.S. Implements New Export Controls to Address National Security Risks Related to Biotechnology

On Jan. 15, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) released an Interim…

Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
| | | |

Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

On Sept. 13, 2024, CSL Seqirus and sa-mRNA pioneer Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor…

USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
| | | | | |

USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

On Jun. 25, 2024, Merck Animal Health announced U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine…

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
| | | |

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…

CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
| | | |

CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…